# Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

> **NCT03473925** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 107 (actual)

## Conditions studied

- Solid Tumors
- Non-small Cell Lung Cancer
- Castration Resistant Prostate Cancer
- Microsatellite Stable Colorectal Cancer

## Interventions

- **DRUG:** Navarixin
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03473925
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-10
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473925, "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03473925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*